



## Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024

October 31, 2024

SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced multiple upcoming posters at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 3-6, 2024 in San Antonio, TX.

**Title:** Novel Oral Small Molecule Dual Amylin and Calcitonin Receptor Agonists for Obesity Treatment

**Poster Number:** Poster 128

**Date/Time:** Sunday, November 3, 7:30 p.m. – 8:30 p.m. CT

**Location:** Exhibit Hall 4

**Title:** Drug Design Principles and Pharmacokinetics/Pharmacodynamics of GSBR-1290, a Small Molecule GLP-1RA

**Poster Number:** Poster 337

**Date/Time:** Monday, November 4, 2:30 p.m. – 3:30 p.m. CT

**Location:** Exhibit Hall 4

**Title:** Significant and Clinically Relevant Weight Changes at 12 Weeks with Small Molecule GLP-1RA, GSBR-1290

**Poster Number:** Poster 342

**Date/Time:** Monday, November 4, 2:30 p.m. – 3:30 p.m. CT

**Location:** Exhibit Hall 4

### About Structure Therapeutics

Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit [www.structuretx.com](http://www.structuretx.com).

### Investors:

Danielle Keatley

Structure Therapeutics Inc.

[ir@structuretx.com](mailto:ir@structuretx.com)

### Media:

Dan Budwick

1AB

[Dan@1abmedia.com](mailto:Dan@1abmedia.com)